文献速递肾癌与肾肿瘤

他拉唑帕利与阿维鲁单抗在基因组定义的转移性肾癌中的2期试验

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-11-07

这项单中心、研究者发起的2期试验评估了聚ADP核糖聚合酶抑制剂(PARPi)他拉唑帕利联合免疫检查点阻断(ICB)阿维鲁单抗在经治转移性肾癌中的疗效。在两个基因组定义的队列中,客观缓解率均为0,中位无进展生存期分别为3.5个月和1.2个月,常见不良事件为乏力、贫血、恶心和头痛,未观察到5级事件。结论认为该联合方案在多种基因组定义的转移性肾细胞癌或肾髓质癌中未显示临床获益。

要点

  • VHL改变队列客观缓解率为0/9,7例最佳疗效为疾病稳定,中位无进展生存期3.5个月。
  • FH/SDH缺陷及肾髓质癌队列客观缓解率为0/8,2例疾病稳定,中位无进展生存期1.2个月。
  • 常见全等级治疗相关不良事件为乏力(61%)、贫血(28%)、恶心(22%)和头痛(22%),3-4级事件7例,无5级事件。

核心结论

  • 首次在晚期肾癌中联合PARPi与ICB的临床研究未在多个基因组定义的转移性肾细胞癌队列或肾髓质癌中显示临床获益。

研究设计与样本

  • 单中心、研究者发起的2期试验,纳入两个基因组选择的晚期肾癌队列:队列1为VHL改变且既往至少接受过一种ICB和一种VEGF抑制剂的肾细胞癌;队列2为FH或SDH缺陷且既往至少接受过一种ICB或VEGF抑制剂的肾细胞癌,以及既往至少接受过一线化疗的肾髓质癌。

主要发现

  • 队列1共10例VHL改变透明细胞肾细胞癌患者,均既往接受过ICB,客观缓解率为0/9(1例因漏服药物不可评估),7例最佳疗效为疾病稳定,中位无进展生存期3.5个月(95%CI 1.0, 3.9个月)。
  • 队列2共8例患者(4例FH缺陷肾细胞癌、1例SDH缺陷肾细胞癌、3例肾髓质癌),6例既往接受过ICB,客观缓解率为0/8,2例最佳疗效为疾病稳定,中位无进展生存期1.2个月(95%CI 0.4, 2.9个月)。
  • 全等级治疗相关不良事件最常见为乏力(61%)、贫血(28%)、恶心(22%)和头痛(22%),3-4级事件7例,无5级事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC), and renal medullary carcinoma (RMC) are affected by genomic instability. Synthetic lethality with poly ADP-ribose polymerase inhibitors (PARPis) has been suggested in preclinical models of these subtypes, and paired PARPis with immune checkpoint blockade (ICB) may achieve additive and/or synergistic effects in patients with previously treated advanced kidney cancers. OBJECTIVE: To evaluate combined PARPi + ICB in treatment-refractory metastatic kidney cancer. DESIGN, SETTING, AND PARTICIPANTS: We conducted a single-center, investigator-initiated phase 2 trial in two genomically selected advanced kidney cancer cohorts: (1) VHL-altered RCC with at least one prior ICB agent and one vascular endothelial growth factor (VEGF) inhibitor, and (2) FH- or SDH-deficient RCC with at least one prior ICB agent or VEGF inhibitor and RMC with at least one prior line of chemotherapy. INTERVENTION: Patients received talazoparib 1 mg daily plus avelumab 800 mg intravenously every 14 d in 28-d cycles. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was objective response rate (ORR) by Immune Response Evaluation Criteria in Solid Tumors at 4 mo, and the secondary endpoints included progression-free survival (PFS), overall survival, and safety. RESULTS AND LIMITATIONS: Cohort 1 consisted of ten patients with VHL-altered ccRCC. All patients had previously received ICB. The ORR was 0/9 patients; one patient was not evaluable due to missed doses. In this cohort, seven patients achieved stable disease (SD) as the best response. The median PFS was 3.5 mo (95% confidence interval [CI] 1.0, 3.9 mo). Cohort 2 consisted of eight patients; four had FH-deficient RCC, one had SDH-deficient RCC, and three had RMC. In this cohort, six patients had previously received ICB. The ORR was 0/8 patients; two patients achieved SD as the best response and the median PFS was 1.2 mo (95% CI 0.4, 2.9 mo). The most common treatment-related adverse events of all grades were fatigue (61%), anemia (28%), nausea (22%), and headache (22%). There were seven grade 3-4 and no grade 5 events. CONCLUSIONS: The first clinical study of combination PARPi and ICB therapy in advanced kidney cancer did not show clinical benefit in multiple genomically defined metastatic RCC cohorts or RMC. PATIENT SUMMARY: We conducted a study to look at the effect of two medications, talazoparib and avelumab, in patients with metastatic kidney cancer who had disease progression on standard treatment. Talazoparib blocks the normal activity of molecules called poly ADP-ribose polymerase, which then prevents tumor cells from repairing themselves and growing, while avelumab helps the immune system recognize and kill cancer cells. We found that the combination of these agents was safe but not effective in specific types of kidney cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kotecha RR, Doshi SD, Knezevic A, et al. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. Eur Urol Oncol. 2023. PMID: 37945488. doi:10.1016/j.euo.2023.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。